Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Clinical Trials

11 recruitingLast updated: June 17, 2026

There are 11 actively recruiting metastatic hormone-sensitive prostate cancer (mhspc) clinical trials across 19 countries. Studies span Phase 3, Phase 1, Phase 2, Not Applicable. Top locations include Salt Lake City, Utah, United States, Jena, Thuringia, Germany, Camperdown, New South Wales, Australia. Updated daily from ClinicalTrials.gov.


Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Trials at a Glance

11 actively recruiting trials for metastatic hormone-sensitive prostate cancer (mhspc) are listed on ClinicalTrialsFinder across 6 cities in 19 countries. The largest study group is Phase 3 with 3 trials, with the heaviest enrollment activity in Salt Lake City, Jena, and Camperdown. Lead sponsors running metastatic hormone-sensitive prostate cancer (mhspc) studies include Bayer, Ankara Etlik City Hospital, and Amgen.

Browse metastatic hormone-sensitive prostate cancer (mhspc) trials by phase

Treatments under study

About Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Clinical Trials

Looking for clinical trials for Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)? There are currently 11 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 111 of 11 trials

Recruiting
Phase 1Phase 2

TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Novartis Pharmaceuticals181 enrolled31 locationsNCT07190300
Recruiting

How Darolutamide Plus Hormone Therapy Works for Men With Advanced Prostate Cancer in Everyday Medical Practice in Germany

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Bayer500 enrolled1 locationNCT07395804
Recruiting

A Study to Learn About How Safe Darolutamide is and How Well it Works in Combination With Androgen Deprivation Therapy and Docetaxel in Routine Medical Care for Japanese Men With Low Volume Metastatic Hormone-Sensitive Prostate Cancer

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)Low-volume Metastasis
Bayer100 enrolled1 locationNCT06661122
Recruiting
Phase 3

A Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Jiangsu HengRui Medicine Co., Ltd.206 enrolled1 locationNCT07241416
Recruiting
Phase 1

Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Amgen60 enrolled14 locationsNCT07140900
Recruiting

Quality of Life, Functional and Cognitive Outcomes in Patients With Metastatic Hormone-Sensitive Prostate Cancer

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Ankara Etlik City Hospital102 enrolled2 locationsNCT07181122
Recruiting

PROCARE - PROstate Cancer Real World Evidence Registry

Prostate CancerMetastatic Castration-resistant Prostate CancerMetastatic Hormone-Sensitive Prostate Cancer (mHSPC)+2 more
UroTrials Company (GmbH)5,000 enrolled53 locationsNCT06835218
Recruiting
Phase 2

Optimal PSA Triggered Individual Management of Androgen Sensitive Prostate Cancer

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
University of Utah160 enrolled1 locationNCT07216248
Recruiting
Not Applicable

Multimodal Approach in Patients With mHSPC. Randomized Trial of APA+ADT vs APA-ADT and Local Treatment

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano566 enrolled3 locationsNCT05649943
Recruiting
Phase 3

ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer

Metastatic Castration-resistant Prostate Cancer (mCRPC)Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Karolinska Institutet750 enrolled32 locationsNCT03903835
Recruiting
Phase 3

Comparing a 6-month vs Long-term Course of Rezvilutamide With ADT Plus Chemotherapy in mHSPC

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
The First Affiliated Hospital with Nanjing Medical University100 enrolled1 locationNCT05956639